Even a cursory glance at the industry will reveal that cannabis stocks have been taking a beating over the last few years. Legalization, once hailed as the ‘Green Rush,’ and fierce competition have eaten into margins andAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (othe ...

Core Insights - The Canadian cannabis sector is evolving with companies adapting to changing consumer demands and global regulations, presenting long-term investment opportunities despite volatility [1][2] - U.S. federal reform is influencing sentiment among Canadian operators, with many maintaining indirect exposure to the U.S. market [1][3] Industry Overview - Companies are diversifying to stabilize revenue during downturns and focusing on cost control and operational efficiency to navigate tighter capital markets [2] - Strong balance sheets provide an advantage to resilient operators as weaker competitors retrench [2] - The sector is prioritizing profitability, cash preservation, and scalable growth over rapid expansion, making financial performance increasingly relevant [4] Company Strategies - **Tilray Brands, Inc. (TLRY)**: Diversified across cannabis, wellness, beverage alcohol, and consumer packaged goods, helping stabilize revenue during slowdowns. It has a strong international presence and indirect access to the U.S. market through hemp-derived products [5][6][10] - **Canopy Growth Corporation (CGC)**: Focused on adult-use and medical cannabis with a disciplined strategy. It has structured interests in U.S. THC and wellness businesses, positioning itself for regulatory changes while maintaining a strong retail presence in Canada [12][15][16] - **Village Farms International, Inc. (VFF)**: Combines cannabis and traditional agriculture, focusing on cultivation efficiency and wholesale distribution rather than dispensary ownership. It has shown significant revenue growth and strong cannabis margins [18][21][22] Financial Performance - Tilray has shown improving stability with record quarterly revenue, supported by beverage alcohol acquisitions and steady cannabis sales. It has moved into a net cash position, emphasizing cost controls and operational discipline [10][11] - Canopy Growth has made measurable progress with improving revenue trends and declining operating expenses, although profitability remains a challenge [16][17] - Village Farms has reported strong revenue growth and record cannabis margins, with positive cash flow supporting its balance sheet strength [21][22]

ATLANTA, Jan. 27, 2026 (GLOBE NEWSWIRE) -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the leading craft beer brand in the Southeast by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), announced the musical lineup for the 2026 Sweetwater 420 Fest taking place April 17-18. The beloved music festival, back for its 21st year, will include headliners like Umphrey’s McGee, Thievery Corporation and Chromeo for the two-day event. The lineup for Friday, April 17th will include Umphrey’s McG ...

Group 1: Market Overview - Cannabis stocks to watch include Tilray Brands, Canopy Growth, Aurora Cannabis, Silver Spike Investment, and Cronos Group, identified by MarketBeat's stock screener tool [2] - Cannabis stocks are characterized by higher regulatory and legal risks, and they tend to be more volatile than the broader market due to changing laws and consumer demand [2] Group 2: Company Profiles - **Tilray Brands (TLRY)**: Engages in research, cultivation, processing, and distribution of medical cannabis, operating in multiple countries including Canada, Australia, and Germany [3] - **Canopy Growth (CGC)**: Involved in the production, distribution, and sale of cannabis and hemp-based products, primarily in the U.S., Canada, and Germany, with operations segmented into Canada Cannabis and International Markets Cannabis [3] - **Aurora Cannabis (ACB)**: Produces and sells cannabis products in Canada and internationally, operating through Canadian Cannabis, European Cannabis, and Plant Propagation segments [4] - **Silver Spike Investment (SSIC)**: A specialty finance company that invests in the cannabis ecosystem through direct loans and equity ownership of privately held cannabis companies [4] - **Cronos Group (CRON)**: Engages in the cultivation and marketing of cannabis products in Canada, Israel, and Germany, offering a variety of products under several brands [5]

Core Insights - SweetWater Brewing Company, a leading craft beer brand in the Southeast, has launched Big Trip Double IPA, a high-ABV extension of its popular Daytrip IPA, featuring a bold 9% ABV and bright citrus notes [3][4]. Product Details - Big Trip is crafted with a blend of Mosaic, Idaho 7, Sultana, Citra, and El Dorado hops, along with 2-row, Pilsner, and Wheat grains, providing a refreshing flavor without the maltiness typical of imperial styles [4]. - The new product will be available in 19.2 oz and 6-pack 12 oz cans, rolling out nationwide in various retail locations [4][5]. Market Trends - Double IPAs are currently the second most popular craft style in the Southeast, with the 19.2 oz can format being the number one style for this category [4][5]. - Tall singles and six packs account for 80% of sales for high-ABV brews in the Southeast, indicating a strong market preference for these formats [5]. Company Background - SweetWater Brewing is recognized for its diverse range of craft beers and is committed to environmental conservation through initiatives like the Save Our Water campaign [6]. - The company is a subsidiary of Tilray Brands, Inc., which operates globally in the cannabis and consumer packaged goods sectors [6][8].

Core Viewpoint - Tilray Medical has rebranded its Italian operations to Tilray Medical Italia, reflecting its commitment to a unified medical cannabis platform in Europe and enhancing its presence in Italy's regulated medical market [1][2][4] Group 1: Strategic Update - The transition to Tilray Medical Italia signifies the company's ongoing efforts to build a scalable medical cannabis platform across Europe [2] - Tilray Medical Italia is expanding its product portfolio with medical cannabis products authorized by the Italian Ministry of Health, in partnership with Molteni Farmaceutici [3][5] Group 2: Market Positioning - Italy is identified as a strategically important market for Tilray Medical, with the rebranding aimed at strengthening local presence and aligning operations under a single global medical brand [4][10] - The company operates within Italy's established medical cannabis framework, supplying products through hospital and pharmacy channels in compliance with national regulations [5][7] Group 3: Product Offerings - Tilray Medical Italia's product portfolio includes various medical cannabis flowers and oils, all EU-GMP certified to meet diverse patient needs [8][9] - The offerings include specific THC and CBD ratios, catering to different therapeutic requirements [9] Group 4: Collaboration and Compliance - The partnership with Molteni Farmaceutici supports physician education, responsible prescribing, and patient access while ensuring high standards for product quality and compliance [6][7] - Tilray Medical Italia aims to responsibly support the evolving demand for medical cannabis in a regulated pharmaceutical environment [7][11]

Core Viewpoint - Tilray Brands has shown some improvement in its financial performance, with a significant increase in international cannabis sales and a reduction in operating losses, but overall growth remains inconsistent and the company continues to face challenges in the cannabis market [1][2][4]. Financial Performance - The company reported a record revenue of $217.5 million for the second quarter of fiscal 2026, marking a 3% increase year over year [2]. - International medical cannabis sales surged by 36%, while beverage sales declined by 21% to $50.1 million [3]. - Operating loss was reduced to $22.3 million from $42.2 million a year ago, attributed to a decline in restructuring costs and amortization expenses [4]. Market Context - The cannabis industry remains volatile, with the potential for short-term gains driven by market excitement, but long-term investment prospects are uncertain [9][10]. - Recent regulatory changes, such as President Trump's executive order to reschedule marijuana, may facilitate research and reduce tax burdens, but do not significantly enhance growth prospects for companies like Tilray [7][8]. Growth Prospects - Despite some positive indicators, Tilray's growth has been inconsistent, often reliant on acquisitions for short-term boosts rather than sustainable organic growth [6]. - The lack of consistent growth and ongoing uncertainty in the cannabis market make Tilray a risky investment, appealing primarily to speculative investors [9][11].

Core Insights - Tilray Brands (TLRY) reported a strong international quarterly performance in Q2 of fiscal 2026, with revenues from its international cannabis business increasing by 36% year over year and 51% sequentially to $20 million, despite facing permit challenges and price compression [1][8] Group 1: International Market Performance - The international cannabis market is a key long-term growth driver for Tilray, supported by increasing market opportunities, revenues, and profitability [2] - The company has reduced supply in the Canadian wholesale market to focus on international markets, maintaining a leading position in Canada across various product categories [2][3] - Tilray's cannabis cultivation capacity has increased to 200 metric tons annually, aiding its expansion into fast-growing markets and improving margins [3] Group 2: Product Expansion and New Markets - Tilray is expanding its beverage business globally, with plans to launch HiBall Energy in the U.K. and further expansion into the Middle East and Africa [4] - The company has entered the Quebec market with vapes under the Good Supply brand, quickly achieving top three SKU positions in the province [3] Group 3: Competitive Landscape - Village Farms International's subsidiary, Pure Sunfarms, is launching 10 new products in the Netherlands, reflecting a focus on innovation and competitive differentiation [5] - SNDL Inc. has acquired five cannabis retail stores in Alberta and Saskatchewan, with plans for further acquisitions in Ontario [6] Group 4: Financial Performance and Valuation - Tilray's shares have increased by 40.4% over the past six months, contrasting with a 6.6% decline in the industry [7] - The company is trading at a forward Price-to-Sales (P/S) ratio of 1.22X, which is lower than the industry average of 2.81X [9]

Core Viewpoint - Tilray Brands is showing signs of recovery after a significant decline in market value over the past five years, with recent positive momentum attributed to regulatory changes and a favorable quarterly update [1][2]. Financial Performance - Tilray reported a record revenue of $218 million for the second quarter of fiscal year 2026, exceeding analyst expectations, although year-over-year growth was only 3% [3]. - The company's gross margin decreased to 26% from 29%, but it reported a narrower net loss of $43.5 million compared to a loss of $85.3 million in the same quarter last year [4]. Regulatory Developments - Positive regulatory changes in the U.S. cannabis market, including the reclassification of cannabis as a Schedule 3 substance, are expected to provide significant opportunities for Tilray [4][6]. - The reclassification allows for easier access to financial services, more medical research into marijuana, and the ability to deduct normal business expenses [6]. Market Expansion - Following the regulatory changes, Tilray is expanding its medical cannabis operations in the U.S. through the launch of Tilray Medical USA, aiming to broaden its portfolio and reach more patients [7].

Core Insights - President Trump's executive order to reschedule cannabis to Schedule 3 is considered a significant shift in federal cannabis policy, potentially alleviating the burdensome tax regime affecting U.S. cannabis operators for decades [1][2]. Tax Implications - The executive order could lead to the elimination of Section 280E of the Internal Revenue Code, which currently taxes legal cannabis operators as if they were narcotics traffickers, preventing them from deducting any business expenses [2][3]. - Rescheduling cannabis to Schedule 3 would allow U.S. companies to deduct standard operating costs, significantly improving their financial health and cash flow [3]. Market Reaction - The cannabis industry is responding positively to the news, especially after a strong performance in 2025, where the AdvisorShares MSOS ETF outperformed the S&P 500 [4]. - Despite the optimistic outlook, the sector is still viewed as highly volatile, with many institutional investors remaining cautious due to past political inaction [4]. Remaining Challenges - Even with the potential rescheduling, U.S. cannabis companies still face hurdles, such as the inability to list on major exchanges like NASDAQ or NYSE, which is available to Canadian companies [5]. - The industry is also awaiting "safe harbor" provisions for banking, which remain unresolved [5]. Stock Performance - Recent performance data for cannabis stocks and ETFs shows varied results, with AdvisorShares Pure U.S. Cannabis ETF (NYSE:MSOS) leading with a 68.55% increase over six months, while other companies like Tilray Brands Inc. (NASDAQ:TLRY) and Canopy Growth Corp. (NASDAQ:CGC) show mixed performance [7].